在接受更昔洛韦治疗的免疫功能低下患者的白细胞中，使用新型人巨细胞病毒DNA定量检测法检测人巨细胞病毒DNA动力学。

Human cytomegalovirus DNA kinetics using a novel HCMV DNA quantitative assay in white blood cells of immunocompromised patients under Ganciclovir therapy.

作者信息

Payan C, Veal N, Sarol L, Villarmé M, Ngohou C, Riberi P, François S, Ifrah N, Loison J, Chennebault J M, Pichard E, Kouyoumdjian S, Lunel F

机构信息

Laboratoire de Virologie, Centre Hospitalier Universitaire, Angers, France.

出版信息

J Virol Methods. 1997 Apr;65(1):131-8. doi: 10.1016/s0166-0934(97)02180-0.

DOI:10.1016/s0166-0934(97)02180-0

PMID:9128870

Abstract

The clearance of human cytomegalovirus (HCMV) was evaluated in infected patients under Ganciclovir (GCV) treatment, using a novel HCMV DNA quantitation assay (HCMV DNA hybrid capture system, Murex Diagnostics). Peripheral white blood cells (WBC) from whole blood specimens of seven AIDS patients, three kidney and two allogeneic bone marrow transplant (BMT) recipients suffering from HCMV disease, were assessed by this method. HCMV DNA 50 and 90% mean clearances were observed at 2.11 +/- 1.97 and 6.22 +/- 4.31 days, respectively, after initial GCV treatment. The viral DNA kinetics were correlated with positive and negative pp65 antigenaemia and viral blood culture. Two-fold higher clearances and initial DNA levels were observed in the AIDS group compared to the transplant group. Neither clinical nor virological relapses were observed under GCV treatment. HCMV DNA quantitation in WBC appears well adapted for a therapeutic follow up of patients with HCMV disease.

摘要

采用一种新型的人巨细胞病毒（HCMV）DNA定量检测方法（HCMV DNA杂交捕获系统，Murex诊断公司），对接受更昔洛韦（GCV）治疗的感染患者体内HCMV的清除情况进行了评估。通过该方法对7例艾滋病患者、3例肾移植患者和2例患有HCMV疾病的同种异体骨髓移植（BMT）受者全血标本中的外周血白细胞（WBC）进行了评估。在开始GCV治疗后，分别在2.11±1.97天和6.22±4.31天观察到HCMV DNA 50%和90%的平均清除率。病毒DNA动力学与pp65抗原血症阳性和阴性以及病毒血培养相关。与移植组相比，艾滋病组的清除率和初始DNA水平高出两倍。在GCV治疗期间未观察到临床或病毒学复发。白细胞中HCMV DNA定量似乎非常适合对HCMV疾病患者进行治疗随访。